[Clinical efficacy of dexamethasone, methotrexate combined with cyclophosphamide for treatment of patients with peripheral T-cell lymphoma].
This study was aimed to investigate the clinical efficacy of dexamethasone, methotrexate combined with cyclophosphamide for treatment of patients with peripheral T-cell lymphoma (PTCL). Twenty-one patients with peripheral T-cell lymphoma were selected as control group, which were received CHOP; twenty-nine patients with peripheral T-cell lymphoma were selected as treatment group, which were received Hyper-CVAD. Clinical efficacy were observed after treatment. In control group 6 patients achieved complete remission(CR), 4 patients achieved partial remission(PR), the total response rate of control group was 47.6%; in treatment group 15 patients achieved CR, 7 patients achieved PR, the total response rate of treatment group was 75.9%, and the total response rate of treatment group was significantly higher than that of control group. The incidence rates of cardiac dysfunction, peripheral neuropathy, anaemia and leucopenia between the two groups had no significant difference. The average progress free survival (PFS) of treatment group was 26.106 months, which was significantly higher than that of control group. The clinical efficacy of dexamethasone, methotrexate combined with cyclophosphamide for treatment of patients with peripheral T-cell lymphoma has been confirmed to be satisfactory and it may be used in clinic.